GSK To Shell Out $21.5M To Exit Wellbutrin Antitrust Suit

Law360, New York (January 14, 2013, 6:32 PM EST) -- A Pennsylvania federal judge on Monday signed off on a $21.5 million settlement between GlaxoSmithKline PLC and employee benefit plans in a class action alleging the pharmaceuticals giant filed sham patent suits to intentionally delay generic competition to its antidepressant Wellbutrin SR.

U.S. District Judge Lawrence F. Stengel granted preliminary approval on the settlement, which was first submitted to the court Dec. 21, between GSK and third-party payor plaintiffs who claimed GSK forced them to pay higher prices for antidepressant Wellbutrin SR and similar drug Zyban...
To view the full article, register now.